Drug Development Archives | 第 9 页，共 26 页 | Certara

Blog

通过模型引导的药物开发促进药物公平：ASCPT 2026 见解

Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…

Certara2026 年 3 月 11 日

Announcement

Certara Announces 2026 Certainty Event

CERTAINTY 2026: Explore AI-driven drug development and technological innovation at the leading biosimulation event for…

Certara2026 年 3 月 9 日

Webinar

Building Trust in Data – Transparency, Traceability, and the Human Element

Danielle Pillsbury2026 年 3 月 5 日

On-Demand Webinar

Virtual Control Groups, Actually: What SEND Makes Possible (and What It Doesn’t)

Learn how SEND enables virtual control groups using historical toxicology data, including key applications, challenges,…

Certara2026 年 3 月 4 日

Publication

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…

Danielle Pillsbury2026 年 3 月 4 日

Blog

ADC 首次人体（FIH）剂量选择：成功设计 FIH 研究的关键

Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…

Certara2026 年 3 月 3 日

Conference

Apotekarsocieteten 临床药理学策略在药物开发中的应用

Danielle Pillsbury2026 年 3 月 2 日

博客

Rare disease day 2026: Accelerating rare disease drug development through cross-functional innovation

On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…

Certara2026 年 2 月 26 日

Live Events

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

–

Diana Marcantonio, PhD2026 年 2 月 24 日

Webinar

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Danielle Pillsbury2026 年 2 月 23 日

© 2026 Certara. 保留所有权力。 | 法律 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software